Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 22, 2017

View Archived Issues

PharmaMar starts phase I study of PM-14 in solid tumors

IPH-5401 development transitions from arthritis to immuno-oncology

Novel OTC gene mutation tied to intermittent hyperammonemia

FDA approves BioCryst's Rapivab in pediatric patients

Paratek's omadacycline awarded third FDA QIDP designation

Novel PI4KII-BETA inhibitors discovered at Stanford, UC Oakland

ATB-200/AT-2221 receives U.S. orphan drug status for Pompe disease

Bill & Melinda Gates Foundation, Anacor present boron-containing pleuromutilins

Bayer discovers new BUB1 inhibitors

Otsuka divulges novel compounds for brain cancer

MUT gene mutation linked to methylmalonic aciduria

Great apes adenovirus multiantigenic vaccine enhances anti-PD1 therapy in vivo

Disarm Therapeutics announces USD 30 million series A financing

Abivax receives French regulatory approval to begin phase IIa study of ABX-464 in ulcerative colitis

FDA grants rare pediatric disease designation to Altemia for SCD in children

DxTerity collaborates with City of Hope on blood test to predict response to radiation therapy

Phase III trial of somavaratan in pediatric growth hormone deficiency does not meet primary endpoint

Cellectar Biosciences, Onconova Therapeutics to jointly develop phospholipid drug conjugates

Phase IIb study of EMI-137 begins

Karyopharm reports first-in-human data for KPT-9274

Soligenix receives funding to support phase III study of SGX-972

Provention Bio in-licenses two clinical-stage assets from Janssen

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 3, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...
5-HT2R allosteric ligands attenuate cocaine use and seeking behavior
BioWorld Science
Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...